On 11 January 2012, orphan designation (EU/3/11/942) was granted by the European Commission to Celator (UK) Ltd, United Kingdom, for liposomal combination of cytarabine and daunorubicin for the treatment of acute myeloid leukaemia.
The sponsorship was transferred to Jazz Pharmaceuticals Ireland Ltd, in December 2016.
Liposomal combination of cytarabine and daunorubicin has been authorised in the EU as Vyxeos since 23 August 2018.
This medicine is now known as daunorubicin / cytarabine.
Liposomal combination of cytarabine and daunorubicin (daunorubicin / cytarabine)
|Disease / condition||
Treatment of acute myeloid leukaemia
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
Fifth Floor, Waterloo Exchange
Tel: +353 1 634 7847
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.